Cancer immunology and immunotherapy: Building on success
Session type: Parallel sessions
The ability to mobilise one's own immune system to target cancer has been recently proven effective in a series of high profile trials where targeting the T cell immune-inhibitory receptor CTLA-4 significantly increased survival of patients with late-stage melanoma. Nonetheless, and despite these promising results, positive and durable responses remain limited to a fraction of the treated patients, underscoring the need for further research in the field.
The goal of this session is to present cutting edge data expanding on the function and relevance of immune checkpoints such as CTLA4, the recent and promising achievements of cellular therapies with chimeric antigen receptors, and the critical and limiting impact that the tumour microenvironment has on immunotherapy.